中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

8 records (took 0.021 seconds)

    REDIRECTED, GENETICALLY-ENGINEERED T REGULATORY CELLS AND THEIR USE IN SUPPRESSION OF AUTOIMMUNE AND INFLAMMATORY DISEASE
    4.
    发明申请
    REDIRECTED, GENETICALLY-ENGINEERED T REGULATORY CELLS AND THEIR USE IN SUPPRESSION OF AUTOIMMUNE AND INFLAMMATORY DISEASE 审中-公开

    公开(公告)号：US20200056152A1

    公开(公告)日：2020-02-20

    申请号：US16361852

    申请日：2019-03-22

    Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD.

    Inventor： Zelig Eshhar ,  Eran Elinav

    IPC: C12N5/0783 ,  A61K39/00

    Abstract: A redirected Treg cell is endowed with specificity toward a selected target antigen or ligand. The cell contains a chimeric receptor polypeptide that is expressed in a single, continuous chain, with an extracellular recognition region displayed on the surface of the cell, a transmembrane region and an intracellular signaling region. The extracellular recognition region is specific for the selected target antigen or ligand. The intracellular signaling region includes a combination of T-cell signaling polypeptide moieties, which combination, upon binding of the extracellular recognition region to the selected target antigen or ligand, triggers activation of the redirected Treg cells to cause suppression of T-cell mediated immunity. Such redirected Treg cells may be used to suppress undesired activity of T effector cells thereby mediating an immune or inflammatory response. They are particularly useful in treating T effector cell-mediated diseases, such as inflammatory bowel disease, transplant rejection and GVH disease.

    Redirected, genetically-engineered T regulatory cells and their use in suppression of autoimmune and inflammatory disease
    7.
    发明授权
    Redirected, genetically-engineered T regulatory cells and their use in suppression of autoimmune and inflammatory disease 有权

    公开(公告)号：US11326147B2

    公开(公告)日：2022-05-10

    申请号：US16361852

    申请日：2019-03-22

    Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD.

    Inventor： Zelig Eshhar ,  Eran Elinav

    IPC: C12N5/0783 ,  A61K39/00

    Abstract: A redirected Treg cell is endowed with specificity toward a selected target antigen or ligand. The cell contains a chimeric receptor polypeptide that is expressed in a single, continuous chain, with an extracellular recognition region displayed on the surface of the cell, a transmembrane region and an intracellular signaling region. The extracellular recognition region is specific for the selected target antigen or ligand. The intracellular signaling region includes a combination of T-cell signaling polypeptide moieties, which combination, upon binding of the extracellular recognition region to the selected target antigen or ligand, triggers activation of the redirected Treg cells to cause suppression of T-cell mediated immunity. Such redirected Treg cells may be used to suppress undesired activity of T effector cells thereby mediating an immune or inflammatory response. They are particularly useful in treating T effector cell-mediated diseases, such as inflammatory bowel disease, transplant rejection and GVH disease.

    Anti-inflammatory peptides and use thereof
    8.
    发明授权
    Anti-inflammatory peptides and use thereof 有权
    抗炎肽及其用途

    公开(公告)号：US09346854B2

    公开(公告)日：2016-05-24

    申请号：US14323408

    申请日：2014-07-03

    Applicant: Yeda Research and Development Co. Ltd.

    Inventor： Yechiel Shai ,  Avner Fink ,  Shay Yaari ,  Tova Waks ,  Zelig Eshhar ,  Christopher J. Arnush

    IPC: C07K7/00 ,  C07K7/08 ,  A61K38/08 ,  C07K14/00

    CPC classification number: C07K7/08 ,  A61K38/08 ,  C07K7/00 ,  C07K14/001

    Abstract: Isolated peptides of 13-30 amino acids comprising 5-9 consecutive repeats of the amino acid pair Alanine-Leucine or Alanine-Valine are provided. The peptides further comprise a stretch of 1-3 Lysine residues present at least at one of the peptide's termini, wherein the only Lysine residue in the isolated peptide is present at the stretch of 1-3 Lysine residues. Pharmaceutical compositions comprising same, methods of treating inflammatory conditions and allergic reactions, as well as methods of neutralizing the activity of lypopolysaccharides are also provided.

    Abstract translation: 提供了包含氨基酸对丙氨酸 - 亮氨酸或丙氨酸 - 缬氨酸的5-9个连续重复的13-30个氨基酸的分离的肽。 所述肽还包含存在于至少一个肽末端的1-3个赖氨酸残基，其中分离的肽中唯一的赖氨酸残基以1-3个赖氨酸残基的一段存在。 还提供了包含其的药物组合物，治疗炎性病症和过敏反应的方法，以及中和赖福多糖活性的方法。

Patent Agency Ranking